Galderma Group AG - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
GALDY Over the counter 2840 www.galderma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galderma Group AG

Galderma Group AG (XSWX:GALD) Full Year 2024 Earnings Call Highlights: Record Sales and ... - Mar 7th, 2025 7:07 am
Galderma Shares Slide on Expected Hit From Investments - Mar 6th, 2025 9:59 am
Galderma to discuss U.S. tariffs with retailers, sees "moving target" - Mar 6th, 2025 6:12 am
Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond - Mar 6th, 2025 6:00 am
AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum - Mar 3rd, 2025 6:00 am
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis - Feb 18th, 2025 6:00 am
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis - Feb 14th, 2025 6:00 am
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™) - Jan 31st, 2025 6:00 am
Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines - Jan 30th, 2025 6:00 am
IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership - Jan 23rd, 2025 6:00 am
Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss - Jan 14th, 2025 6:00 am
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis - Dec 13th, 2024 10:09 pm
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union - Dec 13th, 2024 6:00 am
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis - Nov 28th, 2024 6:00 am
Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation - Nov 4th, 2024 6:00 am
Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends - Oct 25th, 2024 5:00 am
Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance - Oct 24th, 2024 5:00 am
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) - Oct 21st, 2024 5:00 am
Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024 - Sep 17th, 2024 5:00 am
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis - Aug 13th, 2024 5:01 am